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Abstract
Background: Cross-linked hyaluronan—also called Hylan G-F 20—is a medical device developed to treat
osteoarthritis of the knee. However, it is still controversial whether Hylan G-F 20 has a cartilage protective effect in
trauma-induced osteoarthritis. We investigated whether Hylan G-F 20 delayed osteoarthritis progression in a partial
meniscectomized rat model.
Methods: Lewis rats were used for the experiments. The anterior medial meniscus was resected at the level of the
medial collateral ligament in both knees. From 1 week after the surgery, 50 μl of Hylan G-F 20 was injected weekly
into the left knee and phosphate buffered saline was injected into the right knee. Cartilage was evaluated for
macroscopic findings, histology with safranin-o, and expression of type II collagen at 2, 4, and 8 weeks. Synovitis was
also evaluated, and immunohistochemical analysis was performed for ED1.
Results: Macroscopic findings demonstrated that India ink positive area, representing fibrillated cartilage, was
significantly smaller in the Hylan G-F 20 group than in the control group at 2, 4, and 8 weeks (n = 5). There were no
significant differences in osteophyte score between the Hylan G-F 20 group and the control group at 2, 4, and 8 weeks.
Histologically, the cartilage in the medial tibial plateau was destroyed at 8 weeks in the control group, while type II
collagen expression was still observed at 8 weeks in the Hylan G-F 20 group. OARSI score for cartilage histology was
significantly lower in the Hylan G-F 20 group than in the control group at 4 and 8 weeks (n = 5). There were no
significant differences in synovial cell number or modified synovitis score between the Hylan G-F 20 group and the
control group at 2, 4, and 8 weeks (n = 5). In the Hylan G-F 20 group, foreign bodies surrounded by ED1 positive
macrophages were observed in the synovium.
Conclusion: Weekly injections of Hylan G-F 20 starting 1 week after surgery delayed cartilage degeneration after
meniscectomy in a rat model. Synovitis induced by meniscectomy was not alleviated by Hylan G-F 20. Insoluble gels
were observed in the synovium after the Hylan G-F 20 injection.
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Background
Osteoarthritis (OA) is one of the most common musculo-
skeletal diseases and causes joint pain and disability in
daily life. Hundreds of millions of people are suffering
from the disease worldwide [1] and the prevalence of OA
is increasing as the aging population increases [2].
Management of OA is critical from the viewpoint of med-
ical cost, and many efforts have been made to prevent the
progression of OA; however, it is still difficult to overcome
this pathology [3].
Hyaluronan is a constitution of cartilage and synovial
fluid, and contributes to joint homeostasis [4]. In OA,
the synovial fluid is less viscous and both the concentra-
tion and molecular weight of hyaluronan in synovial
fluid decrease [5]; therefore, administration of exogenous
viscous hyaluronan may improve these problems. In the
synovial fluid of the normal joint, the molecular weight
of hyaluronan is 2000–7000 kDa [6–8]. Cross-linked
hyaluronan, Hylan G-F 20, is a medical device developed
to treat OA of the knee and an elastoviscous high mo-
lecular weight fluid derived from chicken combs. Hylan
G-F 20 consists of 80 % Hylan A, a soluble high
molecular weight, and 20 % Hylan B, an insoluble gel.
Hylan A has an average molecular weight of approxi-
mately 6000 kDa and Hylan B is a hydrated gel [9]. It is
reasonable to administrate hyaluronic acid with a mo-
lecular weight similar to that of the normal joint into
OA knees.
In clinical situations, Hylan G-F 20 showed a signifi-
cant reduction in pain for OA patients [10, 11]. One re-
port demonstrated the effectiveness of Hylan G-F 20 for
delaying OA progression [12], while another report
showed opposite results [13]. It is still controversial
whether Hylan G-F 20 has a cartilage protective effect.
In animal studies, Hylan G-F 20 was investigated in a
rabbit anterior cruciate ligament transection model, in
which Hylan G-F 20 was effective in delaying OA pro-
gression [14–16]. We already reported that partial men-
iscectomy induced OA progression in rats and that this
is a useful OA model to examine therapeutic effects
[17–19]. Here, we investigated whether Hylan G-F 20




This study was approved by the Animal Experimental
Committee of Tokyo Medical and Dental University. A
total of 30 10-week-old wild-type male Lewis rats
(Charles River, Kanagawa, Japan) were used for the ex-
periments. They were fed under standard conditions that
changed every week (12-h light:12-h dark cycle, room
air temperature 22–24 °C, 2 rats per cage). The weight
ranged from 280 to 296 g.
Experimental OA model
Rats were anesthetized by isoflurane inhalation and
intraperitoneal injection of 2,2,2-tribromoethanol (Avertin®;
Sigma-Aldrich, Mo.). Both the right and left knee joints re-
ceived surgery. After medial parapatellar incision and lat-
eral dislocation of the patellar tendon, the medial meniscus
was exposed (Fig. 1a). Then the anterior insertional liga-
ment of the medial meniscus was transected to dislocate
the medial meniscus anteriorly, and the medial meniscus
was resected at the level of the medial collateral ligament
(Fig. 1b) [17–19]. The joint capsule and the overlying fascia
were subsequently sutured. The rats were allowed to walk
freely in their cages.
Intra-articular injections of Hylan G-F 20
One week after the surgery, the left knee joint had intra-
articular injections of 50 μl [20] of Hylan G-F 20 (molecu-
lar weight; 6000 kDa, Synvisc®; Teijin Pharma Ltd., Tokyo,
Japan) every week (Fig. 1c). The right knee joint received
weekly injections of phosphate buffered saline (PBS) as a
control (Control Group). The knees were evaluated at 2
(n = 10 for each group), 4 (n = 10 for each group), and 8
(n = 10 for each group) weeks after the surgery (Fig. 1d).
Macroscopic observation
For the evaluation of the medial tibial plateau cartilage,
India ink was brushed on the cartilage surface using a
swab and left for 10 s; then the surface was washed with
a new swab to remove the ink from the intact cartilage
area. Macroscopic pictures were taken using an Olympus
MVX10 microscope (Olympus, Tokyo, Japan) on a dedi-
cated medical photography platform.
India ink positive area on the medial tibial condyle
was quantified using the software Image J (National In-
stitutes of Health, Bethesda, Maryland: Fig. 2b).
The gross finding score in the articular cartilage was
graded as follows: grade 1, intact articular surface; grade
2, minimal osteophyte; grade 3, over spur formation;
grade 4, width of erosion area 0 to 0.5 mm; grade 5,
width of erosion area 0.5 to 1 mm; grade 6, width of ero-
sion area 1 to 1.5 mm; grade 7, width of erosion area 1.5
to 2.0 mm; grade 8, width of erosion area >2.0 mm [21].
The osteophyte score was graded as follows: grade 0,
normal around the medial tibia; grade 1, osteophyte for-
mation 1/3 around the medial tibia; grade 2, osteophyte
formation halfway around the medial tibia; grade 3,
osteophyte formation 2/3 around the medial tibia; grade
4, osteophyte formation all-around the medial tibia.
Histological evaluation of the medial tibial cartilage
The tibial plateau (n = 5 for each group) was fixed in 4 %
paraformaldehyde for 7 days, decalcified in 20 % EDTA so-
lution for 21 days, then embedded in paraffin wax. The
specimens were sectioned in the sagittal plane at 5 μm and
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stained with safranin-o and fast green. Histologic sections
were visualized using an Olympus BX53 microscope
(Olympus, Tokyo, Japan). Cartilage degeneration was
evaluated using the Osteoarthritis Research Society
International (OARSI) score, on a scale of 0–24 points [21].
Immunohistological analysis of the medial cartilage
Paraffin-embedded sections were deparaffinized in xylene,
rehydrated in graded alcohol, and washed with PBS. Then
the samples were pretreated with 0.4 mg/ml proteinase K
(Dako) in Tris HCl buffer for 15 min; then endogenous
peroxidases were quenched using 0.3 % hydrogen peroxid-
ase in methanol for 30 min. Primary antibodies (human
anti–type II collagen; 1:500 dilution [Daiichi Fine Chem-
ical]) were applied to sections and incubated at room
temperature for 1 h. The sections were incubated in the
secondary antibody biotinylated horse anti-mouse IgG for
type II collagen (1:200 dilution; Vector) for 30 min at
Fig. 1 Experimental set up. a Knee joint before and after meniscectomy. Medial meniscus is indicated with white arrow, and meniscal defect with
yellow arrow. b Tibial plateau after meniscectomy. Meniscus defect is indicated with yellow dot. c Study schema. d Study protocol
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Fig. 2 (See legend on next page.)
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room temperature. Immunostaining was detected with
Vectastain ABC reagent (Vector) followed by diaminoben-
zidine staining. The sections were counterstained with
hematoxylin.
Histological and immunohistological analysis of synovium
The whole knee joint (n = 5 for each group) was fixed in
4 % paraformaldehyde for 7 days, decalcified in 20 %
EDTA solution for 21 days, then embedded in paraffin
wax. The specimens were sectioned in the sagittal plane
at 5 μm and stained with hematoxylin and eosin. Histo-
logic sections were visualized using an Olympus BX53
microscope. The number of synovial cells was counted
within the 100 μm of the randomly selected three re-
gions of interest, and the average number was evaluated.
Synovitis was also evaluated using a modified synovitis
score, on a scale of 0–6 points [22]. These quantification
evaluations were performed to examine whether Hylan
G-F 20 improved synovitis; therefore, the area where for-
eign bodies were observed in the Hylan G-F 20 group
was excluded.
The monoclonal mouse anti-rat ED1 antibody [23]
(1:400; Abcam, Cambridge, UK) was used for visualization
of macrophage. For ED1, the sections were placed in 4 %
paraformaldehyde for 15 min, immersed in sodium citrate
buffer (Dako, Carpinteria, CA), placed in hot water at
95 °C for 20 min, and then endogenous peroxidases were
quenched using 0.3 % hydrogen peroxide in methanol
for 30 min. Primary antibodies for ED1 were applied
to sections and kept overnight at 4 °C. After extensive
washes with PBS, the sections were incubated in the
biotinylated horse anti-mouse IgG for ED1 for 30 min
at room temperature. Immunostaining was detected
with Vectastain ABC regent (Vector, Burlingame, CA)
followed by diaminobenzidine staining. The sections
were counterstained with hematoxylin.
Statistical analysis
StatView 5.0 (SAS Institute, Cary, NC) was used for
statistical analyses. Paired t-test was performed for the ana-
lyses. P values less than 0.05 were considered significant.
Results
Hylan G-F 20 delayed cartilage degeneration after
meniscectomy
Macroscopically, in the control group, India ink positive
area was already observed at the medial tibial cartilage
2 weeks after partial resection of the medial meniscus,
and enlarged medially at 4 and 8 weeks (Fig. 2a). In the
Hylan G-F 20 group, India ink positive area was also ob-
served but appeared to be smaller in each period. Quan-
tification analysis (Fig. 2b) demonstrated that India ink
positive area was significantly smaller in the Hylan G-F
20 group than in the control group at 2, 4, and 8 weeks
(Fig. 2c). Gross finding score was also lower in the Hylan
G-F 20 group than in the control group at each period
(Fig. 2d). There were no significant differences in osteo-
phyte score between the Hylan G-F 20 group and the
control group at 2, 4, and 8 weeks (Fig. 2e).
In the control group, stainability of safranin-o in the
medial tibial plateau decreased at 2 weeks, further de-
creased at 4 weeks, and the cartilage was destroyed at
8 weeks (Fig. 3a). In the Hylan G-F 20 group, cartilage
degeneration appeared to be milder than in the control
group in each period and type II collagen expression was
still observed at 8 weeks. OARSI score was significantly
lower in the Hylan G-F 20 group than in the control
group at 4 and 8 weeks (Fig. 3b).
Synovitis induced by meniscectomy was not alleviated by
Hylan G-F 20
The infrapatellar fat pad in the normal knee joint was
covered with a single layer or a few layers of synovial
cells (Fig. 4a). Thickness of synovial lining layers increased
2 weeks after meniscectomy, and then decreased in both
groups. There were no significant differences in synovial
cell number or modified synovitis score between the
Hylan G-F 20 group and the control group at 2, 4, and
8 weeks (Fig. 4b, c).
Foreign bodies were observed in the synovium after the
Hylan G-F 20 injection
In the Hylan G-F 20 group, foreign bodies were observed
in the synovium at the infrapatellar fat pad in 3 knees at
2 weeks, 4 knees at 4 weeks, and 4 knees at 8 weeks
among 5 knees. They were surrounded with multilayered
synovial cells positive for ED1 (Fig. 5).
Discussion
We demonstrated that intra-articular injections of Hylan
G-F 20 delayed cartilage degeneration in a meniscecto-
mized rat OA model. Among the surgically induced ani-
mal models of OA, the menisci resection model has
been widely used [24]. In this study, we removed only
(See figure on previous page.)
Fig. 2 Analyses of macroscopic observations for the medial tibial cartilage. a Macroscopic features stained with India ink. Cartilage erosion is
indicated with arrow. Osteophyte is indicated with arrowhead. b Method for measurement of India ink positive area of the medial tibial plateau.
A boxed area to measure India ink positive area was fixed, the fixed area was gray-scaled, the threshold for India ink positive area was decided,
and India ink positive area was quantified. c Quantification of India ink positive area (n = 5, *p < 0.05, **p < 0.01 by Paired t-test). d Gross finding
score (n = 5, *p < 0.05, **p < 0.01 by Paired t-test). e Osteophyte score (n = 5)
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the anterior part of the medial meniscus. Though total me-
niscus resection models may be more popular [25, 26],
they seem to be highly invasive and complicated. In our
current model, the medial collateral ligament could be pre-
served, and we could complete this model with lower inva-
siveness, with more ease, and with higher reproducibility.
We previously used this model in rats [17, 18, 27, 28],
rabbits [29] and pigs [30]. This model was also used by
other groups [24, 26]. Though our model mimics limited
pathological conditions, it was useful to investigate
the effectiveness of treatment for OA.
Several reports described an anti-inflammatory effect
of hyaluronan injected into the knee joints [31, 32].
Smith et al. injected 500–700 kDa hyaluronan intra-
articularly in an ewe meniscectomy model and reduced
fibrosis [33]. Tang et al. reported that fibrous change of
Fig. 3 Analyses of histological observations for the medial tibial cartilage. a Sagittal sections stained with safranin-o and immunostained with type
II collagen. An 18-week-old rat was used as a normal. Boxed areas in the upper panels are shown at a higher-magnification view in the middle
panels. b OARSI score (n = 5, **p < 0.01 by Paired t-test)
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the infrapatellar fat pad due to strenuous running exer-
cise was inhibited by 800 kDa hyaluronan injection in a
rat model [34]. In this study, Hylan G-F 20 did not im-
prove synovitis induced by meniscectomy. Furthermore,
no evidence was shown for the anti-inflammatory effect
of Hylan G-F 20. This suggests that Hylan G-F 20 de-
layed cartilage degeneration not by an anti-inflammatory
effect, but through refinement of lubrication between
the articular cartilage of the medial femoral condyle and
that of the medial tibial plateau after removal of the an-
terior medial meniscus.
We tested both Hylan G-F 20 and PBS alone in the
same rat, with each knee receiving a different treatment.
The main reason for this was that we wanted to exclude
inter-animal variability and investigate the effect of
Hylan G-F 20 on osteoarthritis progression in a stricter
manner. Additionally, we could cut the number of rats
in half, in comparison to a study design in which either
Hylan G-F 20 or PBS was tested in a rat. One concern is
that injection of Hylan G-F 20 into the knee may affect
the contralateral knee by spreading via systemic circula-
tion. However, this effect will be negligible because the
Fig. 4 Analyses of histological observations for the infrapatellar fat pad. a Sagittal sections stained with hematoxylin and eosin. An 18-week-old
rat was used as a normal. Boxed areas in the upper panels are shown at a higher-magnification view in the lower panels. Arrow indicates increased
number of synovial cells. b Modified synovitis score for infrapatellar fat pad. c Synovial cell number/100 μm synovium
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concentration of hyaluronan in blood hardly increased
after intraarticular injection of Hylan G-F 20 [35].
Before this experiment, we had expected that Hylan
G-F 20 might promote meniscus regeneration, because
Kobayashi et al. reported that injection of 800 kDa
hyaluronan increased the size of the meniscus in a
massive rabbit meniscectomy model [24]. Contrary to
our expectation, we did not find any difference of the
medial meniscus in the Hylan G-F 20 group and the
control group (data not shown); however, a small amount
of regeneration occurred naturally after meniscectomy in
rats [17–19].
In clinical situations, Hylan G-F 20 is injected only 3
times every week [36]. In our protocol, Hylan G-F 20
was injected every week and 7 times to evaluate knees at
8 weeks. This is different from the protocol recom-
mended in clinical situations. We performed weekly in-
jections because we want to compare Hylan G-F 20 and
another hyaluronan, which is injected every week in clin-
ical situations. We are going to report this comparative
study in another paper.
As one possible negative effect of Hylan G-F 20, foreign
bodies surrounded with multilayered macrophages were
observed in the synovium. This was possibly because
Fig. 5 Immunohistochemical analysis of infrapatellar fat pad after the surgery in the Hylan G-F 20 group. Sagittal sections stained with
hematoxylin and eosin, and immunostained with ED1. An 18-week-old rat was used as a normal. Yellow arrow indicates gel in the synovium
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Hylan B, an insoluble gel, was taken up by synovium and
synovitis occurred locally. Foreign bodies in the synovium
were previously reported in other animal studies [37] and
in clinical studies [38]. Sasaki et al. demonstrated the
subcutaneous and intramuscular induction of a delayed
foreign body granulomatous inflammation in guinea pig
and rabbit models [39, 40]. Chen et al. reported that in-
flammation worsened when Hylan G-F 20 was injected
into a patient with hydrarthrosis [38]. Granulomatous
inflammation within the knee has also been described
by Zardawi [41]. Attention must be paid to a foreign body
reaction in clinical use.
There are some limitations in the present study. First,
we injected Hylan G-F 20 1 week after the surgery when
the cartilage degeneration had not yet occurred. There-
fore, repetitive injections of Hylan G-F 20 were effective
for the prevention of the cartilage degeneration, but we
did not identify that this had the same effect in the
established OA model. We should explore this in the
next study. Second, the molecular mechanism of the
chondroprotective effect was not identified from our
study. Synovial inflammation was not attenuated by in-
jections of Hylan G-F 20, which indicates the direct ef-
fect of cartilage protection. However, we should identify
the molecular mechanism of the chondroprotective ef-
fect of Hylan G-F 20. In addition, we used young rats in
this study; therefore, we should take this situation into
consideration when we apply this data to humans. Third,
we used PBS as a control. Each 2.25 mL syringe of Hylan
G-F 20 contains 16 mg of Hylan polymers (hylan A +
hylan B), 17 mg of sodium chloride, 0.32 mg of disodium
hydrogen phosphate, 0.08 mg of sodium dihydrogen
phosphate monohydrate, and 2.0 mL of water. Addition-
ally, the clinical trial for Hylan G-F 20, i.e., physiological
saline, was used as a control [42]. These results suggest
that physiological saline was better than PBS as a control
in our current study. However, PBS was often used as a
control in animal studies to examine the effect of hyalur-
onan [24, 43, 44]. The use of PBS for the control is not
uncommon.
Conclusion
Weekly injections of Hylan G-F 20 starting at 1 week
after surgery delayed cartilage degeneration after men-
iscectomy in rats. Synovitis induced by meniscectomy
was not improved by Hylan G-F 20. Foreign bodies
were observed in the synovium after the Hylan G-F
20 injection.
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